Combining a GLP-1 receptor agonist with a DPP-4 inhibitor provides only a small additional reduction in HbA1c and weight, which is unlikely to justify the potential increased pancreatitis risk and added cost.
Small incremental benefit only6 studies show combination incretin therapy doesn't meaningfully improve outcomes beyond GLP-1 RA monotherapy
What the researchers found
Combining GLP-1 RA and DPP-4 inhibitor provides only a small incremental reduction in HbA1c and weight loss, with the benefit unlikely to offset potential pancreatitis risk and additional cost.
Why it matters
Clinicians sometimes encounter patients on both drug classes, and understanding whether this combination is worthwhile prevents unnecessary polypharmacy, cost, and potential safety risks.
The numbers in context
6 studies from 1,255 screened; small additional HbA1c and weight benefit; hypoglycemia, GI, pancreatitis infrequent
How the study worked
Systematic literature review across five databases (1946-2020). Six studies meeting criteria analyzed for efficacy (HbA1c, weight) and safety (hypoglycemia, GI upset, pancreatitis).
Who was studied
Type 2 diabetes patients on combination GLP-1RA + DPP-4i therapy
What this study cannot tell us
Only 6 studies met criteria, limiting the evidence base. Heterogeneity across studies in drug combinations, doses, and populations. Long-term outcomes not assessed.
How to read the evidence
Systematic review limited by the small number of qualifying studies (n=6). Provides moderate-quality evidence against combination incretin therapy.
When this study was published
Published in 2021, with database searches through April 2020.
The bigger picture
Both GLP-1 RAs and DPP-4 inhibitors work through the incretin system, so combining them targets overlapping mechanisms. This review confirms the pharmacological expectation that adding a DPP-4 inhibitor to a GLP-1 RA — which already maximally activates GLP-1 receptors — yields diminishing returns.
Questions still open
- Should patients on dual incretin therapy be deprescribed to monotherapy?
- Are there specific patient subgroups who might benefit from combination incretin therapy?
- How does combination incretin therapy compare to GLP-1 RA plus SGLT2 inhibitor?
Common questions
Should I take both a GLP-1 drug and a DPP-4 inhibitor for diabetes?
What's a better combination than dual incretin therapy?
Read the original research
Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.
Journal of clinical pharmacy and therapeutics, 46(1), 28-34
Citation
Cowart, Kevin; Updike, Wendy H; Lloyd, Andie; Bullers, Krystal. (2021). Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.. Journal of clinical pharmacy and therapeutics, 46(1), 28-34. https://doi.org/10.1111/jcpt.13270